Esperion Therapeutics, Inc., a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Its lead product candidate is Bempedoic acid, an inhibitor of ATP-citrate lyase that reduces cholesterol biosynthesis that is in Phase III long-term safety and tolerability study. Esperion Therapeutics, Inc. was founded in 2008 and is headquartered in Ann Arbor, Michigan.
http://www.priceseries.com/trade/ESPR-Esperion-Therapeutics-Inc-stock-gains-15-percent-a-Trade-Record-by-priceSeries-2019050320190529.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments